Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: Results of an international phase 2 study

Blood

Volumn 126, Issue 12, 2015, Pages 1415-1423

  Donadieu, Jean ^a   Bernard, Frederic ^b   Van Noesel, Max ^c   Barkaoui, Mohamed ^a   Bardet, Odile ^b   Mura, Rosella ^d   Arico, Maurizio ^e   Piguet, Christophe ^f   Gandemer, Virginie ^g   Alla, Corinne Armari ^h   Clausen, Niels ⁱ   Jeziorski, Eric ^b   Lambilliote, Anne ^j   Weitzman, Sheila ^k   Henter, Jan Inge ^l   Van Den Bos, Cor ^m  

^a ARMAND TROUSSEAU HOSPITAL   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^d Ospedale Microcetemico Pediatric Hematology Oncology   (Italy)

^e Azienda sanitaria provinciale (ASP)   (Italy)

^f LIMOGES UNIVERSITY HOSPITAL   (France)

^g RENNES UNIVERSITY HOSPITAL   (France)

^h GRENOBLE UNIVERSITY HOSPITAL   (France)

ⁱ AARHUS UNIVERSITY HOSPITAL   (Denmark)

^j LILLE UNIVERSITY HOSPITAL   (France)

^k HOSPITAL FOR SICK CHILDREN   (Canada)

^l KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^m EMMA CHILDREN S HOSPITAL   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; CORTICOSTEROID; CYTARABINE; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; VINBLASTINE; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; DIARRHEA; DISEASE ACTIVITY SCORE; ENTERITIS; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; INFECTION; LANGERHANS CELL HISTIOCYTOSIS; LIVER; LUNG ASPERGILLOSIS; MAINTENANCE THERAPY; MALE; MULTICENTER STUDY; MYALGIA; OVERALL SURVIVAL; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SPLEEN; TREATMENT RESPONSE; CLINICAL TRIAL; DRUG EFFECTS; HISTIOCYTOSIS, LANGERHANS-CELL; LANGERHANS CELL; PATHOLOGY; RECURRENT DISEASE; SURVIVAL; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; CHILD, PRESCHOOL; CLADRIBINE; CYTARABINE; FEMALE; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LANGERHANS CELLS; LIVER; MALE; RECURRENCE; SPLEEN; SURVIVAL ANALYSIS; SURVIVAL RATE; VINBLASTINE;

EID: 84942922162     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-03-635151     Document Type: Article

References (29)

1. Gadner H, Grois N, Arico M, et al; Histiocyte Society. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr. 2001;138(5):728-734.
2. Gadner H, Grois N, Pötschger U, et al; Histiocyte Society. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood. 2008;111(5): 2556-2562.
3. Gadner H, Minkov M, Grois N, et al; Histiocyte Society. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013;121(25):5006-5014.
4. Haupt R, Minkov M, Astigarraga I, et al; Euro Histio Network. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer. 2013;60(2):175-184.
5. Minkov M, Grois N, Heitger A, Pötschger U, Westermeier T, Gadner H; DAL-HX Study Group. Response to initial treatment of multisystem Langerhans cell histiocytosis: An important prognostic indicator. Med Pediatr Oncol. 2002; 39(6):581-585.
6. The French Langerhans' Cell Histiocytosis Study Group. A multicentre retrospective survey of Langerhans' cell histiocytosis: 348 cases observed between 1983 and 1993. The French Langerhans' Cell Histiocytosis Study Group. Arch Dis Child. 1996;75(1):17-24.
7. Berry DH, Gresik MV, Humphrey GB, et al. Natural history of histiocytosis X: A Pediatric Oncology Group Study. Med Pediatr Oncol. 1986; 14(1):1-5.
8. Bernard F, Thomas C, Bertrand Y, et al. Multicentre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer. 2005; 41(17):2682-2689.
9. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1-10.
10. Donadieu J, Piguet C, Bernard F, et al. A new clinical score for disease activity in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2004; 43(7):770-776.
11. Minkov M, Grois N, Broadbent V, Ceci A, Jakobson A, Ladisch S. Cyclosporine A therapy for multisystem Langerhans cell histiocytosis. Med Pediatr Oncol. 1999;33(5):482-485.
12. Jakobson AM, Kreuger A, Hagberg H, Sundström C. Treatment of Langerhans cell histiocytosis with alpha-interferon. Lancet. 1987;2(8574): 1520-1521.
13. Henter JI, Karlén J, Calming U, Bernstrand C, Andersson U, Fadeel B. Successful treatment of Langerhans'-cell histiocytosis with etanercept. N Engl J Med. 2001;345(21):1577-1578.
14. Akkari V, Donadieu J, Piguet C, et al; French Langerhans Cell Study Group. Hematopoietic stem cell transplantation in patients with severe Langerhans cell histiocytosis and hematological dysfunction: experience of the French Langerhans Cell Study Group. Bone Marrow Transplant. 2003;31(12):1097-1103.
15. Steiner M, Matthes-Martin S, Attarbaschi A, et al. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant. 2005; 36(3):215-225.
16. Weitzman S, Braier J, Donadieu J, et al. 29-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). Results of the LCH-S-98 protocol of the Histiocyte Society. Pediatr Blood Cancer. 2009;53(7): 1271-1276.
17. Abraham A, Alsultan A, Jeng M, Rodriguez- Galindo C, Campbell PK. Clofarabine salvage therapy for refractory high-risk Langerhans cell histiocytosis. Pediatr Blood Cancer. 2013;60(6): E19-E22.
18. Simko SJ, Tran HD, Jones J, et al. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease. Pediatr Blood Cancer. 2014;61(3): 479-487.
19. Apollonsky N, Lipton JM. Treatment of refractory Langerhans cell histiocytosis (LCH) with a combination of 2-chlorodeoxyadenosine and cytosine arabinoside. J Pediatr Hematol Oncol. 2009;31(1):53-56.
20. Pant C, Madonia P, Bahna SL, Bass PF, Jeroudi M. Langerhans cell histiocytosis, a case of Letterer Siwe disease. J La State Med Soc. 2009; 161(4):211-212.
21. Hu T, Liu R, Li J, et al. Cladribine for 13 cases refractory high-risk children Langerhans cell histiocytosis [in Chinese]. Zhonghua Xue Ye Xue Za Zhi. 2014;35(11):985-989.
22. Rosso DA, Amaral D, Latella A, Chantada G, Braier JL. Reduced doses of cladribine and cytarabine regimen was effective and well tolerated in patients with refractory-risk multisystem Langerhans cell histiocytosis [published online ahead of print May 5, 2015]. Br J Haematol.
23. Crews KR, Gandhi V, Srivastava DK, et al. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol. 2002;20(20): 4217-4224.
24. Yamada K, Yasui M, Sawada A, Inoue M, Nakayama M, Kawa K. Severe persistent bone marrow failure following therapy with 2-chlorodeoxyadenosine for relapsing juvenile xanthogranuloma of the brain. Pediatr Blood Cancer. 2012;58(2):300-302.
25. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919-1923.
26. Berres ML, Lim KP, Peters T, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014;211(4):669-683.
27. Charles J, Beani JC, Fiandrino G, Busser B. Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation. J Am Acad Dermatol. 2014;71(3):e97-e99.
28. Haroche J, Cohen-Aubart F, Emile JF, et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF (V600E)-mutated Erdheim-Chester disease. J Clin Oncol. 2015;33(5):411-418.
29. Héritier S, Jehanne M, Leverger G, et al. Vemurafenib use in an infant for high-risk Langerhans cell histiocytosis [published online ahead of print April 30, 2015]. JAMA Oncol.